不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel:ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Dynamic Mortality Modeling: Incorporating Predictions of Future General Population Mortality Into Cost-Effectiveness Analysis.
Dynamic Mortality Modeling: Incorporating Predictions of Future General Population Mortality Into Cost-Effectiveness Analysis.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
动态方法的应用在技术上简单,并有可能对成本效果分析的估计产生有意义的影响。
卫生经济学模型通常采用一般人群观察到的死亡率模拟队列未来死亡情况。这种方法可能存在问题,因为死亡率统计记录的是过去,而非对未来的预测。我们提出一种新型动态一般人群死亡率建模方法,使分析者能够纳入死亡率未来变化的预测,并通过案例说明从传统静态方法转向动态方法可能产生的影响。
我们复现英国国家卫生与临床优化研究所(NICE)TA559评估中使用的axicabtagene ciloleucel(axi)治疗弥漫大B细胞淋巴瘤模型。全国死亡率预测数据来自英国国家统计局。按年龄和性别划分的死亡率逐个模型年度更新:模型第1年采用2022年死亡率,第2年采用2023年死亡率,以此类推。对年龄分布作出4种不同假设:固定平均年龄、对数正态分布、正态分布和伽马分布。将动态模型结果与传统静态方法比较。
采用动态计算后,一般人群死亡率所对应的未折现生命年增加2.4–3.3年。在案例研究中,这使折现增量生命年增加0.38–0.45年(8.1%–8.9%),可接受的经济价格相应提高14,456–17,097。
动态方法技术上简单,并可能对成本效果分析的估算产生实质影响。因此,我们呼吁卫生经济学家和卫生技术评估机构今后采用动态死亡率建模。
Health economic models commonly apply observed general population mortality rates to simulate future deaths in a cohort. This is potentially problematic, because mortality statistics are records of the past, not predictions for the future. We propose a new dynamic general population mortality modeling approach, which enables analysts to implement predictions of future changes in mortality rates. The potential implications of moving from a conventional static approach to a dynamic approach are illustrated using a case study.
The model utilized in National Institute for Health and Care Excellence appraisal TA559, axicabtagene ciloleucel axi for diffuse large B-cell lymphoma, was replicated. National mortality projections were taken from the UK Office for National Statistics. Mortality rates by age and sex were updated each modeled year with the first modeled year using 2022 rates, the second modeled year 2023 and so on. A total of 4 different assumptions were made around age distribution: fixed mean age, lognormal, normal, and gamma. The dynamic model outcomes were compared with those from a conventional static approach.
Including dynamic calculations increased the undiscounted life-years attributed to general population mortality by 2.4 to 3.3 years. This led to an increase in discounted incremental life-years within the case study of 0.38 to 0.45 years (8.1%-8.9%), and a commensurate impact on the economically justifiable price of 14 456 to 17 097.
The application of a dynamic approach is technically simple and has the potential to meaningfully affect estimates of cost-effectiveness analysis. Therefore, we call on health economists and health technology assessment bodies to move toward use of dynamic mortality modeling in future.
MEMBER ACCOUNT
登录成功会直接打开下一页。